

JUN 28 2007



**HAMRE, SCHUMANN,
MUELLER & LARSON, P.C.**
AN INTERNATIONAL INTELLECTUAL PROPERTY FIRM

FAX TRANSMISSION June 28, 2007

TO: Mail Stop: AMENDMENT
 Examiner: B.J. FETTEROLF
 Commissioner for Patents
 PO Box 1450
 Alexandria, VA 22313-1450

FROM: Douglas P. Mueller

OUR REF: 14633.0001US01

TELEPHONE: (612) 455.3800

Total pages, including cover letter: 6


PTO FAX NUMBER: 571.273.8300

If all pages are NOT received, please call us at 612.455.3800 or fax us at 612.455.3801.

Title of Document: AMENDMENT UNDER 37 C.F.R. §1.111

Applicant: SUMIDA
 Serial No.: 10/626502
 App. Filed: July 23, 2003
 Group Art No.: 1642


Please charge any additional fees or credit overpayment to Deposit Account No. 50-3478. Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

By: 
 Name: Douglas P. Mueller
 Reg. No. 30,300

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

Tracy Kimmel

Signature


 Date: June 28, 2007

225 SOUTH SIXTH STREET · SUITE 2650 · MINNEAPOLIS · MN 55402
 TEL. 612.455.3800 · FAX 612.455.3801
 WWW.HSML.COM · MAIL@HSML.COM

RECEIVED
CENTRAL FAX CENTER


JUN 28 2007

S/N 10/626502

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	SUMIDA ET AL.	Examiner:	B.J. FETTEROLF
Serial No.:	10/626502	Group Art Unit:	1642
Filed:	July 23, 2003	Docket No.:	14633.0001US01
Title:	AGGLUTINATION ACCELERATOR FOR IMMUNOLOGICAL MEASUREMENT		

CERTIFICATE UNDER 37 CFR 1.6(d):
I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on June 28, 2007.

By: 
Name: Tracy Kimball

Mail Stop: AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

AMENDMENT UNDER 37 C.F.R. §1.111

In response to the Office Action mailed May 7, 2007, please amend the above-identified application as indicated herein.

Amendments to the Claims begin on page 2 of this paper and a Listing of Claims is provided.

Remarks begin on page 5 of this paper.